Scientists in Asia and Africa are racing to discover hardier crop varieties using gene editing tools. But patent restrictions ...

Researchers from the University of Illinois have reported complementary discoveries that will improve scientists' ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...

Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the ...

Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our ...

A new kind of cancer gene therapy can be remotely activated at a specific part of the body. The team developed a version of ...

Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

作为RNA特异性靶向工具，CRISPR/Cas13技术提供了一种强大而有效的方法，这种精度对于揭示多种类型RNA在植物生长发育过程中的作用，如发育、应激反应等至关重要，这为植物功能研究和作物改良提供了新的技术手段。

该研究开发的CrisprAIE，是一种将CRISPR/Cas反应与“一到多”AIEgen发光荧光读取相结合的技术（图1）。这种“一到多”的AIEgen发光读出是通过使用AIEgen负载的双链DNA（dsDNA） reporters实现的，这些 ...

在2024年美国血液学会年会上公布的试验数据显示，异体CAR-T细胞疗法CTX112耐受性良好，并能在经过多次先前治疗的患者中产生完全缓解。研究包括12名受试者，剂量范围从30 x 106到600 x 106 CAR+ T细胞。结果显示，在所有剂量水平上，客观反应率为67%，完全反应率为50%。

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% ...